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Abstract
Combination with other small molecule drugs represents a promising strategy to improve therapeutic efficacy of FLT3
inhibitors in the clinic. We demonstrated that combining ABT-869, a FLT3 inhibitor, with SAHA, a HDAC inhibitor, led to
synergistic killing of the AML cells with FLT3 mutations and suppression of colony formation. We identified a core gene
signature that is uniquely induced by the combination treatment in 2 different leukemia cell lines. Among these, we showed
that downregulation of PTP4A3 (PRL-3) played a role in this synergism. PRL-3 is downstream of FLT3 signaling and ectopic
expression of PRL-3 conferred therapeutic resistance through upregulation of STAT (signal transducers and activators of
transcription) pathway activity and anti-apoptotic Mcl-1 protein. PRL-3 interacts with HDAC4 and SAHA downregulates PRL-
3 via a proteasome dependent pathway. In addition, PRL-3 protein was identified in 47% of AML cases, but was absent in
myeloid cells in normal bone marrows. Our results suggest such combination therapies may significantly improve the
therapeutic efficacy of FLT3 inhibitors. PRL-3 plays a potential pathological role in AML and it might be a useful therapeutic
target in AML, and warrant clinical investigation.
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Introduction
Internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-
ITD) mutation occurs in about 25% of AML patients and is
associated with poor prognosis [1,2,3]. In contrast to their
impressive potency in cell culture system, current FLT3 inhibitors
as single agent predominantly induce transient reduction of
peripheral, but not bone marrow blasts in clinical trials [4].
Combination with other small molecule drugs represents a
promising strategy to improve therapeutic efficacy of FLT3
inhibitors in clinic.
Histone acetylation and deacetylation, controlled by the balance
of histone acetyltransferase (HAT) and histone deacetylase
(HDAC), play a key role in regulating gene expression by
changing chromatin structure. Small molecule HDAC inhibitors
(HDACi) have proven to be a promising new class of anticancer
drugs against hematological malignancies [5], as well as solid
tumors [6]. Suberoylanilide hydroxamic acid (SAHA, VorinostatH)
is the first HDACi that obtained US FDA approval for the
treatment of relapsed or refractory cutaneous T-cell lymphoma
(CTCL).
SAHA has also been examined in a combinatory fashion with
other classes of anticancer agents in acute leukemias. Combination
of SAHA with cyclin-dependent kinase (CDK) inhibitor flavopir-
idol results in marked apoptosis through the downregulation of
short-lived pro-survival proteins XIAP and Mcl-1 in AML cells
[7]. Co-exposure of 17-allylamino- 17-demethoxygeldanamycin
(17-AAG), a HSP90 antagonist, with SAHA induces profound
mitochondrial damage and apoptosis through the inactivation of
ERK activity and a block in p21
WAF1 induction in leukemia cells
[8]. Furthermore, inactivation of Akt and activation of c-Jun N-
terminal kinase (JNK) has been identified as the mechanism of
synergistic antileukemic effect between 2-medroxyestradiol (2-ME)
and SAHA [9]. Specifically, HDAC inhibitors have been reported
to synergistically interact with PKC412, a FLT3 inhibitor.
LAQ824, a cinnamyl hydroxamate HDAC inhibitor, downregu-
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chaperone protein HSP90, which stabilizes mutant FLT3 receptor
[10,11]. These data suggest that combination of HDAC inhibitors
with different types of antitumor therapies might engage distinct
molecules and signaling transduction pathways.
ABT-869, a multiple receptor tyrosine kinase inhibitor, inhibits
FLT3 phosphorylation and signaling and is now in active clinical
cancer therapeutic development [12]. In this study, we showed
that combination of ABT-869 and SAHA has synergistic anti-
leukemic activity. This study identified that PRL-3, a metastasis-
associated gene, was a downstream target of FLT3-ITD signaling
and played a role in the synergism. In addition, PRL-3 itself could
be a new therapeutic target in AML.
Results
Synergistic cytotoxicity of combination of ABT-869 and
SAHA in leukemia
MV4-11 cells (M5) expressed exclusively the mutated allele of
FLT3-ITD. MOLM-14 cells (M5) bear one allele of FLT3-ITD
and the other allele of wild-type FLT3. We first determined the
effect of HDACi on MV4-11 and MOLM-14 cells. Leukemia cell
lines were treated with SAHA at increasing concentrations of 1 to
10 mM for 48 hours. MTS assays were used to determine the
inhibition of cell proliferation. The ED50 of SAHA on MV4-11
and MOLM-14 was 4 mM and 5 mM respectively as determined
by CALCUSYN software. Subsequently, we set about determining
whether concurrent exposure of MV4-11 and MOLM-14 cells to
ABT-869 and SAHA would result in enhanced cytotoxicity. As
shown in Fig. 1A and 1B, the CI values at ED50,E D 75 and ED90
ranged from 0.6 to 0.87, indicating synergistic effect.
To determine whether the combination therapy synergistically
induce apoptosis, the Annexin-V/PI double staining was used to
assess MV4-11 and MOLM-14 cells treated with ABT-869 and
SAHA. Although exposure of MV4-11 and MOLM-14 cells to either
ABT-869 or SAHAalone at indicated dosesdid not induce significant
Annexin-V positive cells, the combination therapy demonstrated a
marked increase in apoptosis in both cell lines (p,0.001, Fig. 1C).
Importantly, individual drug exposure led to a modest expression of
cleaved PARP, a hallmark of apoptosis. In contrast, co-treatment
with ABT-869 and SAHA resulted in a remarked increase in cleaved
PARP expression, indicating superior lethality (Fig. 1D).
These data therefore confirmed that combination of ABT-869
and SAHA resulted in significantly synergistic anti-leukemia effect
in MV4-11 and MOLM-14 cells.
ABT-869 and SAHA function synergistically to inhibit
colony forming of AML cell lines and induce apoptosis in
primary AML cells
Next, we investigated the cytotoxic effect of the combination
treatment of ABT-869 and SAHA on clonogenic activity of MV4-
11 and MOLM-14 cells. As shown in Fig. 2A and 2B, ABT-869
and SAHA alone moderately reduced the clonogenic activity of
MV4-11 and MOLM-14. However, cotreatment with ABT-869
and SAHA not only significantly increased the loss of clonogenic
survival of MV4-11 and MOLM-14 cells (p,0.01), but also
decreased the size of the colonies in general, as compared to
treatment with either of the drugs alone.
We further validated the findings by studying primary human
leukemia. Primary cells from 3 patients with FLT3-ITD and 3
patients with wild type (wt) FLT3 were incubated with either
DMSO, ABT-869 20 nM, SAHA 4 mM and in combination for
48 hours, followed by FACS analysis of Annexin V/PI double
staining. Enhanced induction of apoptosis by combination
treatment was observed in all the 3 primary AML samples with
FLT3-ITD (all p values,0.001, Fig. 2C, left panel). However, the
same combination treatment did not induced greater cell death as
compared to SAHA alone in patients with wt-FLT3, while ABT-
869 had little effect as expected (Fig. 2C, right panel).
Identifying core gene signature crucial for the synergism
between ABT-869 and SAHA
To elucidate the molecular mechanism of the synergistic lethality
between ABT-869 and SAHA, we compared the gene expression
profiles of MV4-11 and MOLM-14 cells treated with DMSO
control, ABT-869, SAHA and combination therapy using the
Affymetrix microarray platform. We focused on delineating a core
gene signature unique and common to the combination therapy in
both MV4-11 and MOLM-14, which could reveal important
molecularinsightsintothetherapeuticsynergyweobserved.Table1
summarizes genes differentially induced more than two-fold by the
combination therapy in both cell lines. The expression changes of
some of the genes involved in cancer metastasis, cell cycle, DNA
repair, DNA binding and cell proliferation, including Phosphatase
of regenerating liver-3 (PRL-3, also named as PTP4A3), ORC1L,
MND1, ZNF85 and LMO4 were confirmed by RQ-PCR at the
mRNA level (Table S1 and Figure S1).
Modulation of PRL-3 influenced drug sensitivity
Among the top 5 downregulated genes, was PRL-3, a metastasis-
associated gene, which has been shown to be oncogenic in several
types of solid tumors. The finding that PRL-3 was significantly
down-regulated by combination therapy prompted us to further
explore the role of PRL-3 in the synergistic cytotoxicity. To
investigate the effect of different treatment on PRL-3 protein
expression, MOLM-14 cells were treated with control, ABT-869
6 nM, SAHA 4 mM, or combination. After 48 hours, cells were
harvested for Western blot analysis. ABT-869 substantially reduced
PRL3 protein and the combination therapy completely inhibited
PRL-3 expression (Fig. 3A). To examine the role of FLT3 signaling
in the synergism and regulation of PRL-3, we analyzed the
expression of p-FLT3, FLT3 as well as p-Stat5, and Stat5, a
downstream target of FLT3 pathway. In agreement with the
changes on PRL-3, we observed the parallel change of p-FLT3, i.e.,
the inhibition was more profound in combination treated sample
compared to ABT-869 alone (Fig. 3A). These data suggest that this
synergistically anti-leukemic effect is FLT3 signaling-dependent.
Next, we established a PRL-3 over-expressing cell line, MOLM-
14-PRL3 and the increased PRL-3 expression confirmed by
Western blot analysis was 3-fold (Fig. 3B, inserted picture). Cells
were treated with ABT-869, or SAHA at different concentrations,
or in combination for 48 hr, followed by assessment of apoptosis.
As shown in Fig. 3B, cells transduced with PRL-3 were more
resistant not only to ABT-869 and SAHA as single agents, but also
to the combination therapy, as compared with cells transduced
with empty vector (p,0.05). Consistent with these results, the
reduction of PRL-3 protein was also less in MOLM-14-PRL3 cells
undergoing different treatments (Figure S2).
We next tested the effect of targeting PRL-3 on ABT-869-
mediated cytotoxicity. We used shRNA approach to specifically
knockdown PRL-3 in MOLM-14 cells, and then evaluated the cell
viability after ABT-869 incubation by apoptosis assay. Among 3
different shRNA clones tested, RHS3939-98490780 (shRNA-
0780) produced best knockdown effect. The approximately 90%
downregulation of PRL-3 by shRNA-0780 was validated by
Western blot analysis (Fig. 3C, inserted picture). We further
observed that cells treated with PRL-3 shRNA-0780 were more
sensitive to ABT-869, SAHA, and combination treatment as
PRL-3 in AML with FLT3-ITD
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p,0.05). In addition, we treated MOLM-14 cells with the small
molecular PRL-3 inhibitor I, 2-Bromobenzyl-rhodanine derivative
[13], for 48 h and observed increased portion of apoptotic cells
(Fig. 3D, p,0.01) and reduction of PRL-3 protein in a dose-
dependent manner (Fig. 3E).
Figure 1. Antileukemic effect of the combination of ABT-869 with SAHA on leukemia cell lines with FLT3-ITD mutations.
Combination indices (CIs) quantitatively describe the interactions between ABT-869 and SAHA in MV4-11 cells (A), MOLM-14 cells (B). The X-axis
shows inhibitory effect by the combination of two drugs and Y-axis shows the CI values. ED stands for effective dosage. The CI values at ED50,E D 75
and ED90 values of two drugs were inserted into the figures. These results were generated by CalcuSyn software. (C) Percentage of apoptosis induced
by ABT-869 alone, SAHA alone, and combination treatment for 48 hours. The experiments were in triplicate. Comb 1*: Combination of ABT-869 3 nM
and SAHA 2 mM, p,0.001 as compared to either single drug treatment. Comb 2**: ABT-869 6 nM+SAHA 4 mM, p,0.001 as compared to either single
drug treatment. (D) Western blot analysis of cleaved PARP in MV4-11 and MOLM-14 cells. b-actin was used as loading control. Cells were treated with
either control, ABT-869 3 nM for MV4-11 and 6 nM for MOLM-14, SAHA 4 mM or combination therapy for 48 hours, and then followed by lysis and
Western blot analysis.
doi:10.1371/journal.pone.0019798.g001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19798Figure 2. Combination treatment enhances loss of clonogenic survival and apoptosis of AML cells. (A) MV4-11 cells were treated with
DMSO control, ABT-869 3 nM, SAHA 2 mM for 48 hours. (B) MOLM-14 cells were treated with DMSO control, ABT-869 6 nM, SAHA 2 mM for 48 hours.
In both (A) and (B), cells were washed and plated in HSC-CFU media for 7 days. Representative pictures were presented in the right panel. The colony
number was expressed as mean 6 SD of average of 5 random 40 times fields.
wp,0.01 as compared to single drug treatment. (C) Primary AML cells
with FLT3-ITD mutation (left panel) or wt-FLT3 (right panel) were incubated with DMSO, ABT-869 20 nM, SAHA 4 mM and combination for 48 hours,
followed by FACS analysis of apoptosis. The bar graphs show percentage of apoptotic cells. The experiments were duplicated. *p,0.001 as compared
to single drug treatment in all the three primary AML patient samples with FLT3-ITD mutation.
doi:10.1371/journal.pone.0019798.g002
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PRL-3 mediated drug resistance, we profiled a panel of anti-
apoptotic proteins in MOLM-14-Mock and MOLM-14-PRL3
cells. Western blot analysis revealed that Mcl-1 was strikingly
increased, followed by marginal upregulation of c-IAP1 and
XIAP, while Bcl-xL, Bcl-2 and Survivin didn’t increase in
MOLM-14-PRL3 cells as compared to MOLM-14-Mock cells
(Fig. 4A). Importantly, high level of Mcl-1 has been implicated in
development and maintenance of both solid tumors and
haematological malignancies and contributes to drug resistance
[14]. Mcl-1 is regulated by several signalling pathways, including
PI3K/Akt, MAPK/ERK and Stat pathways [14]. To that end, we
further assessed the activities of the PI3K/Akt, MAPK/ERK and
Stat pathways in these two isogenic cell lines. Interestingly,
phosphorylated Stat5 (p-Stat5) and p-Stat3 were distinctly
elevated, whereas p-ERK1/2 was minimally increased and there
was virtually no change of p-Akt (Fig. 4B).
Taken together, these data demonstrate a role for PRL-3 in
mediating drug resistance in AML through Stat activation and
upregulation of Mcl-1, and the down-regulation of PRL-3
accounts for much of the synergistic effect between SAHA and
ABT-869, which is dependent on FLT3 signaling.
The association between PRL-3 expression and FLT3-ITD
mutation in AML
Oncomine is a web-based cancer microarray database,
including 28000+ cancer transcriptome profiles. A search of the
Oncomine database (December 09) revealed that PRL-3 was
significantly overexpressed in FLT3-ITD positive AML as
compared to FLT3-ITD negative AML (study name: Valk_leuke-
mia, 78 vs 206 cases, p,0.001, Figure S3) [15], indicating a
possible association between PRL-3 expression and FLT3-ITD
mutation. Furthermore, when we examined the PRL-3 protein
expression in two isogenic leukemia cell lines, TF-1 and TF1-ITD
(stable cell line transfected with FLT3-ITD cDNA) [16], we found
that the parental TF-1 cells were negative for PRL-3 protein. In
sharp contrast, TF1-ITD showed abundant PRL-3 expression
(Fig. 5A). To further validate the association between PRL-3 and
FLT3, we treated the TF1-ITD cells with 2 nM and 5 nM of
ABT-869. ABT-869 dose-dependently inhibited the expression of
p-FLT3 and p-Stat5, as well as PRL-3 (Fig. 5B). We previously
reported that indirubin derivative (IDR) E804, a specific Stat
(Signal Transducer and Activator of Transcription) signaling
inhibitor, reverses the resistance to FLT3 inhibitor in AML [12].
Here, we evaluated the role of Stat signaling in regulation of PRL-
3. The data obtained showed the treatment with IDR E804 was
effective in inhibiting Stat activity (p-Stat5) and reducing PRL-3
protein level (Fig. 5C). These results together with previous
experiments showing that inhibition of PRL-3 by ABT-869 alone
and combination treatment (Fig. 3.A) suggested PRL-3 could be a
novel downstream molecule of FLT3-ITD signaling.
SAHA, a pan-HDAC inhibitor, targets both classes I and II
HDAC enzymes [17]. To investigate the possible direct association
ofPRL-3withHDACs,weundertookco-immunoprecipitation(Co-
IP) of MOLM-14 cell lysate using anti-PRL-3 antibody. HDAC4
Table 1. List of core gene signature identified by Affymetrix microarray studies of MV4-11 and MOLM-14 cells treated with
combination of ABT-869 and SAHA.
Probe ID Gene Name Description Fold Change
1553743_at FAM119A family with sequence similarity 119, member A 23.3
212975_at DENND3 DENN/MADD domain containing 3 22.3
209695_at PTP4A3 protein tyrosine phosphatase type IVA, member 3 22.5
205085_at ORC1L origin recognition complex, subunit 1-like (yeast) 22.9
223700_at MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) 22.8
206572_x_at ZNF85 zinc finger protein 85 22.7
225362_at FAM122B family with sequence similarity 122B 22.6
209608_s_at ACAT2 acetyl-Coenzyme A acetyltransferase 2 22.4
221750_at HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 23.1
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 22.7
213008_at KIAA1794 KIAA1794 22.1
226817_at DSC2 desmocollin 2 22.5
214297_at CSPG4 Chondroitin sulfate proteoglycan 4 (melanoma-associated) 22.9
228385_at DDX59 DEAD (Asp-Glu-Ala-Asp) box polypeptide 59 22.1
1553972_a_at CBS cystathionine-beta-synthase 22.5
226181_at TUBE1 tubulin, epsilon 1 22.4
1560023_x_at --- CDNA FLJ37333 fis, clone BRAMY2020106 2.3
204072_s_at FRY furry homolog (Drosophila) 2.3
209205_s_at LMO4 LIM domain only 4 2.2
228315_at --- CDNA clone IMAGE:5261213 2.3
206332_s_at IFI16 interferon, gamma-inducible protein 16 2.6
208966_x_at IFI16 interferon, gamma-inducible protein 16 2.8
226030_at ACADSB acyl-Coenzyme A dehydrogenase, short/branched chain 2.3
Minus numbers denote the expression of the gene is decreased.
doi:10.1371/journal.pone.0019798.t001
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IgG control as shown in Fig. 5D. The interaction between HDAC4
and PRL-3 appeared specific, because Western blot analysis of
HDAC1, 2, 3, 5, 6, 7 in the same immunoprecipiated complex
turned out to be negative (data not shown). To further confirm the
interaction between HDAC4 and PRL-3, PRL-3 complex were
immunoprecipiated from cell lysate of colon cancer DLD-1 cells
transfected with GFP-hPRL3 plasmid using anti-GFP antibody and
screened for the presence of HDAC enzymes. Again, only HDAC4
was detected in the immunoprecipiated complex (Fig. 5.E and data
not shown). These results demonstrated that HDAC4 bound to
PRL-3 protein. To address the question of whether reduction of
PRL-3 by SAHA was mediated through proteasome degradation,
MOLM-14 cells were treated with SAHA, MG-132, a proteasome
inhibitor, or SAHA plus MG-132. Western blot analysis showed the
protein level of PRL-3 was decreased approximately 50% as
compared to control sample, but this SAHA-induced inhibition of
PRL-3 was blocked in the presence of proteasome inhibitor MG-
132 (Fig. 5.F). Thus, these data implied that SAHA-related
degradation of PRL-3 requires proteasome pathway.
To further assess PRL-3 expression in patients with AML, we
used the PRL-3-specific monoclonal antibody clone 318 to stain
paraffin-embedded bone marrow sections of 19 newly diagnosed
AML patients. We detected PRL-3 protein expression in 47% (9
out of 19) of AML samples (Fig. 6A and 6B), whereas PRL-3
expression is absent in 6 out 8 normal bone marrow samples
(Fig. 6C). In 2 normal bone marrow samples, PRL-3 was detected
in pre-erythrocytes, which is consistent with previous report from
Figure 3. Impact of modulation of PRL-3 expression on drug sensitivity. (A) MOLM-14 cells were treated with DMSO, ABT-869 6 nM, SAHA
4 mM or combination therapy for 48 hours, and then followed by lyses and Western blot analysis of PRL-3, p-Stat5, Stat5. Immunoprecipitation (IP)
was performed using anti-p-Tyrosine antibody, followed by Western blot with anti-FLT3 antibody. The same blot was then stripped and reprobed
with anti-FLT3 antibody. The upper band is160 kDa glycosylated mature FLT3 and the lower band is 130 kDa nonglycosylated FLT3. (B) MOLM-14
cells were transfected with vector control (Mock) or pLVX-puro-PRL3 vector. Cells were treated with either ABT-869 6 nM, SAHA 4 mM or combination
therapy for 48 hours. (C) MOLM-14 cells were transfected with control and PRL-3 shRNA-0780 respectively for 48 hours, and then treated with ABT-
869 3 nM, SAHA 2 mM or combination therapy for 72 hours. Apoptosis assay was used to determine the cell viability in different treatments. (D) Flow
cytomertric analysis of apoptosis in MOLM-14 cells were treated with either DMSO control or PRL-3 inhibitor I at concentration 2 and 10 mM for 48 h.
(E) Effect of PRL-3 inhibitor I on PRL-3 protein expression. Apoptosis data shown represents the means of three independent experiments 6 SD
(*p,0.01, **p,0.05).
doi:10.1371/journal.pone.0019798.g003
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of patients are FLT3-ITD positive. This indicates PRL-3 could
play a pathological role in leukemogenesis in AML, in particular,
FLT3-ITD positive AML.
Discussion
We have demonstrated, in this study, the synergistic effect with
the combination of ABT-869 and SAHA, a multi-targeted tyrosine
kinase inhibitor and HDACi, a similar finding reported in a
previous study using two related compounds [10]. However, we
further have elucidated distinctive important downstream molec-
ular mechanisms mediating this synergism, resulting in the
identification of a novel signaling downstream of FLT3 involving
PRL-3. Our data suggest a model in which the enhanced
downregulation of PRL-3 is due to targeting two different
pathways by ABT-869 and SAHA (Fig. 7). ABT-869 inhibits
PRL-3 expression through suppression of FLT3-ITD and
downregulated Stat pathways, while SAHA mediated degradation
of PRL-3 is dependent on proteasome pathway (Fig. 7).
The PRL-3 gene encodes a 22-kDa tyrosine phosphatase that has
been implicated in tumorigenesis and metastasis [19,20]. Saha et al.
reported exceptionally higher expression of PRL-3 in liver
metastatic CRCs as compared to non-metastatic CRCs and normal
colon epithelium [21]. Mechanistic studies reveal that PRL-3
functions as an initiator of neoplastic angiogenesis by recruiting
endothelial cells [18] and stimulates invasion and motility of tumor
cells through activating the Rho family of small GTPases such as
RhoA and RhoC [22]. Increasing activities of Src kinase and PI3K/
AKT signaling pathways via negative feedback regulation of C-
terminal Src kinase (Csk) and PTEN tumor suppressor gene
respectively by PRL-3 also contribute to its oncogenic role
[23,24,25]. PRL-3 has been identified as a downstream target gene
of p53 and it dose-dependently regulates cell-cycle progression [26].
Recently, we discovered that a trans-factor-PCBP1 (PolyC-RNA-
binding protein 1) suppressed PRL-3 translation via binding three
GC-motifs of the 59 UTR of PRL-3 mRNA and an inverse
correlation between PCBP-1 and PRL-3 protein levels in different
solid tumors [27]. These findings highlight a fundamental role of
PRL-3 in tumor development. In contrast to extensive studies in
solid tumors, the role of PRL-3 in hematological malignancies is
much less appreciated. To our knowledge, only one study reported
that PRL-3 promotes human multiple myeloma (MM) cell
migration and overexpression in a subset of MM patients assessed
by gene expression profiling [28]. Herein, for the first time, we show
that PRL-3 may play a role in drug resistance in AML and that
modulation of PRL-3 expression plays a role in the synergistic
antileukemic effect of co-treatment of ABT-869 and SAHA in
FLT3-ITD positive AML. Importantly, our study uncovers a novel
mechanism of PRL-3 mediated drug resistance by which PRL-3
activates Stat pathways and subsequently upregulates Mcl-1,
conferring resistance to small molecule inhibitors. Higher level of
Figure 4. Comparisons of a panel of anti-apoptotic proteins and signaling transduction pathways in MOLM-14-Mock and MOLM-
14-PRL3 cells. The two isogenic cells were lysed and subjected to 10% to 12% SDS-PAGE. Western blots were detected with the indicated
antibodies for the assessment of expression level changes in anti-apoptotic proteins (A) and PI3K/Akt, MAPK/ERK and Stat pathways (B). b-actin was
used as a loading control. Arrow highlighted Mcl-1.
doi:10.1371/journal.pone.0019798.g004
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targeted therapies such as PKC412, another FLT3 inhibitor [29]
and HDAC inhibitors [30], as well as ABT-737, a Bcl-2 antagonist
[31]. Notably,inthepresentstudy,we demonstrate that PRL-3may
be a novel downstream target of FLT3-ITD signaling and
expression of PRL-3 mRNA is significantly higher in AML patients
with FLT3-ITD compared to wild type FLT-3. Furthermore, PRL-
3 is aberrantly expressed in about half of AML cases, including 67%
of FLT3-ITD positive AML samples in our study. The exact
mechanism(s) by which some FLT3-ITD positive patients don’t
express PRL-3 protein remain elusive and are under further
investigation. The full clinical implication of aberrant PRL-3
expression in AML will require study in a much larger patient
population. Nevertheless, as PRL-3 is aberrantly expressed and
pathologic relevance in a substantial number of AML, it may
represent a good therapeutic target in this subset of AML.
Developing small molecular inhibitor against phosphatases is
currently an active area of research for cancer treatment [32]. In
addition, monoclonal antibody targeting PRL-3 has recently been
shown to inhibit metastasis of PRL-3-expressing cancer cells in
murine xenograft models [33]. This clinical implication of PRL-3
targeted therapy in AML is under active investigation by our group.
In summary, we observed therapeutic synergism between ABT-
869, a FLT3 and multi-targeted tyrosine kinase inhibitor, and
SAHA, an HDAC inhibitor. We further elucidated the molecular
basis for the synergism. In particular, our study highlights the
critical role of PRL-3 in drug resistance and potential pathogenesis
of AML. In addition, PRL-3 is aberrantly expressed in substantial
number of AML, both with and without FLT3-ITD, suggesting
that PRL-3 may have a significant role in leukemogenesis and
could be a novel therapeutic target in PRL-3 positive AML.
Materials and Methods
Cell lines and primary patient samples
MV4-11, MOLM-14 and TF1-ITD cells were cultured with
RPMI1640 (Invitrogen, Carlsbad, CA) supplemented with the
addition of 10% of fetal bovine serum (FBS, JRH Bioscience Inc,
Lenexa, KS) at density of 5610
5 cells/ml in a humid incubator
with 5% CO2 at 37uC. TF-1 cells were cultured in RPMI1640
completed medium with 2 ng/ml human IL-3 (PeproTech, Rocky
Hill, NJ). Bone marrow (BM) blast cells (.90%) from newly
diagnosed AML patients were obtained at National University
Hospital (NUH) in Singapore. The detection of FLT3 mutations
was reported previously [34].
Ethics Statement
This study was approved by Institutional Review Board (IRB) of
National University of Singapore and BM samples were obtained
with written informed consent.
Figure 5. The association of PRL-3 and FLT3-ITD in AML. (A) Western blot assessment of PRL-3 protein in two isogenic cell lines, TF-1 and TF1-
ITD. b-actin was used as loading control. (B) TF1-ITD cells were treated with DMSO, ABT-869 2 nM and 5 nM for 48 hours, and then followed by IP and
Western blot analysis as described in Fig. 4.A. (C) MOLM-14 cells were treated with DMSO control or IDR E804 100 nM for 48 h. The cells were then
lysed, and analysed by immunoblotting using anti-p-Stat5, anti-Stat5, anti-PRL-3 clone 318 and anti-b-actin. (D) MOLM-14 cell lysate was
immunoprecipitated with anti-PRL-3 or anti-IgG antibody. The immunoprecipitates were immunoblotted with anti-HDAC4 antibody. (E) DLD-1-GFP-
hPRL3 cell lysate was immunoprecipitated with anti-GFP or ant-IgG antibody, followed by immunoblotting analysis with anti-HDAC4 antibody. Total
cellular extracts (inputs) were used as positive controls. (F) Western blot analysis of cell lysates extracted from MOLM-14 cells treated with DMSO,
SAHA 4 mM, MG-132 10 mM or SAHA plus MG-132. The incubation duration of DMSO and SAHA was 24 h and MG-132 was added 4 h before harvest
of cells. Densitometric analysis was performed using Amersham Image Scanner with LabScan ImageQuant TL Software. The level of PRL-3 was
normalized with each b-actin level.
doi:10.1371/journal.pone.0019798.g005
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ABT-869 was kindly provided by Abbott Laboratories (Chi-
cago, IL). ABT-869 was dissolved in dimethyl sulfoxide (DMSO)
at concentration of 10 mM as stock kept in 220uC. SAHA was
purchased from BIOMOL (Plymouth Meeting, PA). PRL-3
Inhibitor I (catalogue number P0108) and MG-132 were obtained
from Sigma (St. Louis, MO) and dissolved in DMSO.
Cell proliferation and apoptosis assays
Leukemic cells were seeded in 96-well culture plates at a density
of 2610
4 viable cells/100 ml/well in triplicates, and were treated
with ABT-869, SAHA or combination therapy. Colorimetric
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(MTS assay, Promega, Madison, WI) was used to determine the
cytotoxicity. IC50 was determined by MTS assay [12] and
calculated with CalcuSyn software (Biosoft, Cambridge, UK).
Each experiment was triplicated. For apoptosis assay, MV4-11
and MOLM-14 cells were cultured in the presence of either ABT-
869, SAHA alone or in combination for 48 hours. Cells were
washed twice with 16 Phosphate-Buffered Saline (PBS), stained
with Annexin V/Propidium Iodide (PI, BD PharMingen, San
Jose, CA), and immediately analyzed by a DakoCytomation Cyan
LX flow cytometry (DakoCytomation, Glostrup, Denmark).
Combination index calculation
The CalcuSyn software (Biosoft, Cambridge, UK) was used to
analyze dose-effect relationships according to the method of Chou
and Talalay [35]. The combination index (CI) was applied to
quantitatively describe synergism defined as a greater-than-
additive effect from a combination of two agents (CI,1),
antagonism as a less-than-additive effect (CI.1), and an additive
effect as (CI=1). The CI values were calculated according to the
levels of growth inhibition (Fraction affected, Fa) by each agent
individually and combination of ABT-869 with SAHA. Specifi-
cally, the equation is: CI=(D)1/(Dx)1+(D)2/(Dx)2+(D)1(D)2/
(Dx)1(Dx)2, where (D)1 indicates ABT-869 and D2 represents
SAHA and Dx stands for the doses ABT-869 and SAHA alone,
respectively, inhibiting x%. Constant ratio combinations of the
two drugs at 0.256, 0.56,1 6,2 6and 46of their ED50 was used.
Western blot analysis
Preparation of the cell lysate and immunoblotting were
performed as previously described [36], except for PRL-3 analysis,
16% gel was used. Anti-PRL3 antibody was clone 318 as reported
previously [37].
Co-immunoprecipitation (Co-IP) and immunoblotting
Anti-PRL-3 antibody clone 318 was attached to protein A/G
agarose beads by using Pierce Crosslink IP Kit (Thermo Scientific,
Rockford, IL) according to the manufacture’s recommendation.
Anti-GFP antibody conjugated agarose and anti-HDAC6 anti-
body were purchased from Santa Cruz biotechnology (Santa Cruz,
CA). Histone Deacetylase (HDAC) Antibody Sampler Kit
containing HDAC1, 2, 3, 4, 5, 7 was purchased from Cell
Signaling Technologies (Danvers, MA). The establishment of the
stable DLD-1 cell transfected with GFP-hPRL3 was reported
previously (reference 32). Approximately 2610
7 MOLM-14 or
DLD-1-GFP-hPRL3 cells were washed twice with ice-cold
16PBS. Lysis was carried out on ice in NP-40 buffer (50 mM
Tris-HCl, 150 mM NaCl, 1% NP-40, pH 8.0) containing Halt
TM
Protease inhibitor cocktail (EDTA-free) (Pierce, Thermo Scientif-
ic), phosphatase inhibitor cocktail I and II (Sigma-Aldrich, St
Louis, MO, USA). The lysates were immunoprecipitated with the
primary antibody overnight at 4, and the immunocomplexes were
Figure 6. Evaluation of PRL-3 protein expression in bone marrow sections from primary AML patients and normal donors by IHC.
(A) A representative image from nine PRL-3 positive AML cases was shown. PRL-3 positive signals were detected in the cytoplasm of myeloid cells. (B)
A representative result from ten PRL-3 negative AML cases was shown. (C) A normal bone marrow image from 6 donors was presented. The original
magnifications were 636.
doi:10.1371/journal.pone.0019798.g006
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resuspended in SDS sample buffer. Immunoprecipitates were
boiled for 5 min, briefly centrifuged, and separated on 7.5% SDS-
PAGE. Membranes were probed with the appropriate antibodies,
and proteins recognized by the antibodies were detected using the
Chemiluminescent Detection Kit (Pierece, Thermo Scientific).
Colony forming capacity assay
MV4-11 and MOLM-14 cells were treated with ABT-869, SAHA
or combination for 48 hours, then washed twice with 16PBS. After
that, about 3000 cells from control and drug-treated cells were plated
in MACSH HSC-CFU media complete with Epo (Miltenyi Biotec
GmbH, Germany) in 6-well plates and cultured for 7 days at 37uCi n
a5 %C O 2 incubator. Colonies consisting of more than 50 cells were
counted under an inverted microscope. Total 5 random 4610
magnification fields were selected and average number of colonies of
each sample was calculated. The experiments were duplicated.
Microarray study
For the microarray experiments, MV4-11 and MOLM-14 cells
were treated with DMSO control, ABT-869 3 nM, SAHA 6 mM
and combination therapy for 24 hours. Cells were then washed in
PBS and high-quality total RNA was extracted RNeasy Midi Kit,
according to the manufacturer’s instruction (Qiagen, Valencia,
USA). RNA quantity, quality, and purity were assessed with the
use of the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara CA, USA).
Gene expression profiling was performed using Affymetric
U133plus2.0 gene chip (Affymetrix, Santa Clara, CA, USA)
according to the manufacturer’s protocol. Biological triplicates
were performed for each sample. Three lists of genes with 2 fold or
more difference in gene expression between treatment and control
were generated as follows: ABT-869 alone versus DMSO control,
SAHA alone versus DMSO control and ABT-869 plus SAHA
versus DMSO control. This analysis was done separately for the
MV4-11 and MOLM-14 cell lines and the final gene lists were
genes that were unique to the ABT-869 and SAHA combination
in both cell lines. Expression profiles were deposited into the Gene
Expression Omnibus data repository (GSE accession # 26114)
and are MIAME compliant.
Construction and infection of PRL-3-expression vector
The human full-length cDNA of PRL-3 was purchased from
Open Biosystems (Huntsville, AL) and inserted into EcoRI/
BamH Is i t e so fl e n t i v i r u sp L V X - p u r ov e c t o r( C l o n t e c h ,M o u n -
tain View, CA), This pLVX-puro-PRL3 construct was validated
by sequencing. Plasmid vectors were transfected into HEK
293T/17 packaging cells (ATCC) using Lentiphos
TM HT
protocol (Clontech, PT3984-2) as recommended by the
manufacturer. High-titer viral particle-containing medium were
harvested 48 h after transfection and used to infect MOLM-14
cells with 8 mg/mL polybrene (Millipore, Billerica, MA). Two
days after infection, cells were transferred to fresh medium
constituting 90% RPMI1640, 10% Tet System Approved FBS
(Clontech) and 2 mg/mL puromycin (Millipore) for selection of
transduced cells.
Short-hairpin (shRNA) RNA study
Control and 3 human PRL-3 specifically pLKO.1 lentiviral
shRNAs (RHS3939-9570404, -98490774 and -98490780) were
purchased from Open Biosystems (Huntsville, AL, USA). Three
million of MOLM-14 cells were mixed with viral supernatant and
8 mg/ml of polybrene (Millipore) and centrifuged at 2500 rpm for
90 min at 30uC. After additional incubation at 37uC for 4 hours,
the medium was changed to fresh complete medium. Two days
later, half of cells were harvested and followed by protein
extraction and Western blot analysis of PRL-3 expression and
the other half of cells were treated with different dose of ABT-869.
Immunohistochemistry (IHC) analysis of primary AML
bone marrow samples
AML patients with various genetic backgrounds as well as 3
normal controls were identified and bone marrow samples were
retrieved from NUH tissue bank in accordance with the
Declaration of Helsinki and the protocol was approved by the
Institutional Review Board. Standard indirect immunoperoxidase
procedures were used for immunohistochemistry with anti-PRL-3
specific antibody (clone 318) [37]. We used Dako EnVision
TM
Systems K 1395 (Dako, Carpinteria, CA) to perform IHC
experiments.
Supporting Information
Figure S1 Real-time quantitative-PCR validation of
some gene changes in the core gene signature identified
by microarray studies. (A) RQ-PCR quantification of PRL-3
gene. (B) RQ-PCR quantification of ORCL1 gene. (C) RQ-PCR
quantification of MND1 gene. (D) RQ-PCR quantification of
ZNF85 gene. (E) RQ-PCR quantification of LMO4 gene.
(DOC)
Figure 7. Schematic representation of the molecular mecha-
nisms of enhanced downregulation of PRL-3 by combination
treatment with ABT-869 and SAHA. ABT-868-induced inhibition of
PRL-3 is due to targeting upstream FLT3-ITD and Stat pathway. HDAC4
physically interacts with PRL-3. SAHA mediated degradation of PRL-3 is
dependent on the proteasome pathway.
doi:10.1371/journal.pone.0019798.g007
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MOLM- `4 cells transfected with empty vector (Mock) or
PRL-3 after treatment with either ABT-869 6 nM alone,
SAHA 4 mM alone or combination therapy for 48 hours.
Beta-actin was used as loading control. Densitometric analysis was
performed using Amersham Image Scanner with LabScan
ImageQuant TL Software. The level of PRL-3 was normalized
with respective b-actin level.
(DOC)
Figure S3 The association of PRL-3 and FLT3-ITD in
AML. Comparison of PRL-3 expression between FLT3-ITD
positive (Class 2) and others (Class 1, FLT3-ITD negative) AML
patients. The box plot was generated by Oncomine based on the
study of Valk P, et al (reference 15). The difference is statistically
significant (p,0.001).
(DOC)
Table S1 The sequences of primers used in real-time
PCR.
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